Globus Medical director Tobin sold his entire stake for $3.1 million five days after a guidance cut

A director's entire position, gone in one day

James R. Tobin, an 81-year-old Globus Medical▼−0.22% — Globus Medical, down 0.22 percent today (NYSE: GMED) director who ran Boston Scientific▼−0.20% — Boston Scientific, down 0.20 percent today from 1999 to 2009 and has sat on this board since August 2015, now owns nothing in the company ¹². On November 10 he exercised his final three option tranches, granted in 2019, 2020 and 2021 at strike prices from $43.58 to $65.05, then sold all 41,666 shares at weighted averages of $75.10 and $75.68 ¹.

Gross proceeds came to $3.13 million against $2.35 million of exercise cost, a pre-tax spread of about $786,000 ³. The options did not expire until 2029, 2030 and 2031, so no deadline forced this ¹. The filing reports no Rule 10b5-1 plan↗, the pre-committed selling schedule insiders use to trade blind ¹³.

Five days after the outlook came down

Globus cut its 2026 revenue forecast to $3.09 billion, from $3.18 billion to $3.22 billion, on November 5, after third-quarter sales of $763.7 million fell short of the $792.4 million analysts expected ⁴⁵. Net income still rose 18.7% to $141.2 million on cost cuts, and the board added $500 million to its buyback while reaffirming adjusted EPS guidance of $4.95 to $5.05 ⁶.

A second director, audit committee chair Ann Rhoads, sold 5,000 shares at $85.00 on November 4 under a 10b5-1 plan dated June 10, 2026 ⁷. Her sale was scheduled. Tobin's came after the cut, without a plan, at prices roughly $10 lower ⁵. BMO downgraded the stock on November 6 ⁵.

The bull case runs through margins

Chief Financial Officer Kyle Kline framed the buyback as "confidence in our long-term growth profile," and part of the record supports him: eight straight quarters of sequential adjusted gross margin expansion, Enabling Technologies revenue up 24%, and 73% more surgical robot and navigation units placed than a year earlier ⁴. Excluding Nevro, the stimulator maker Globus bought for $252.5 million, base sales still grew 3% ⁶.

Analysts carry a $93.43 mean target against the November 12 close of $72.30 ⁵. Tobin's exit also has a benign reading: he is 81, the board's guidelines↗ ask independent directors to offer to resign after age 72, and his term runs to 2027 ².

London is the next chance to explain it

Management presents at the Jefferies Global Healthcare Conference in London on November 18↗ at 11:30 GMT, its first public stage since both the cut and the sale ⁸. The board offered shareholders $500 million of buybacks in the same week one director chose to hold nothing ⁸. Watch whether Tobin serves the term he was elected to, and whether any more Form 4s land before that webcast starts ⁸.